報價延遲最少15分鐘:2025/07/20 16:50 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.25 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.18/-0.33
|
|
企業價值
620.12M
|
| 資產負債 |
|
每股賬面淨值
3.32
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
64.38M
|
|
每股收益
1.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 16:50 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). |
